Mode
Text Size
Log in / Sign up
N/A Completed N=100 Prevention

RexMedical- Option* Vena Cava Filter IDE Study

Source: ClinicalTrials.gov NCT00488865 ↗
Enrolled (actual)
100
Serious AEs
65.0%
Results posted
Aug 2010
Primary outcomePrimary: Percentage of Participants With Clinical Success — 88 Percent of Participants

Summary

This study is designed to evaluate the safety and efficacy of the RexMedical Option* Vena Cava Filter in the treatment of patients who are at increased risk for Pulmonary Embolism and require caval interruption.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Clinical Success
88 —
PRIMARY
Percentage of Participants With Retrieval Clinical Success
92 —
SECONDARY
Placement Technical Success
100 —

Eligibility Criteria

Key Inclusion Criteria

  • Patient is at least 18 years of age
  • Patient requires temporary or permanent caval interruption

Key Exclusion Criteria

  • Patient has pre-existing filter implanted in her/her vasculature or has undergone filter retrieval within 60 days prior to study device implant
  • Patient is currently enrolled in another investigational device or drug trial
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00488865). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search